JP2005520795A5 - - Google Patents

Download PDF

Info

Publication number
JP2005520795A5
JP2005520795A5 JP2003551316A JP2003551316A JP2005520795A5 JP 2005520795 A5 JP2005520795 A5 JP 2005520795A5 JP 2003551316 A JP2003551316 A JP 2003551316A JP 2003551316 A JP2003551316 A JP 2003551316A JP 2005520795 A5 JP2005520795 A5 JP 2005520795A5
Authority
JP
Japan
Prior art keywords
hsp90
high affinity
assay
compound
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003551316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005520795A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/039993 external-priority patent/WO2003050295A2/en
Publication of JP2005520795A publication Critical patent/JP2005520795A/ja
Publication of JP2005520795A5 publication Critical patent/JP2005520795A5/ja
Pending legal-status Critical Current

Links

JP2003551316A 2001-12-12 2002-12-12 Ｈｓｐ９０阻害活性を有するプリン類似体 Pending JP2005520795A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34076201P 2001-12-12 2001-12-12
PCT/US2002/039993 WO2003050295A2 (en) 2001-12-12 2002-12-12 Assays and implements for determining and modulating hsp90 binding activity

Publications (2)

Publication Number Publication Date
JP2005520795A JP2005520795A (ja) 2005-07-14
JP2005520795A5 true JP2005520795A5 (enExample) 2006-02-02

Family

ID=23334832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003551316A Pending JP2005520795A (ja) 2001-12-12 2002-12-12 Ｈｓｐ９０阻害活性を有するプリン類似体

Country Status (6)

Country Link
US (2) US20050074457A1 (enExample)
EP (1) EP1519735A4 (enExample)
JP (1) JP2005520795A (enExample)
AU (1) AU2002364566B2 (enExample)
CA (1) CA2468202A1 (enExample)
WO (1) WO2003050295A2 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670113B2 (en) * 2001-03-30 2003-12-30 Nanoprobes Enzymatic deposition and alteration of metals
US7691598B2 (en) * 2001-03-30 2010-04-06 Nanoprobes, Inc. Method for detecting a target molecule by metal deposition
US7892781B2 (en) * 2001-03-30 2011-02-22 Nanoprobes, Inc. Detecting a target using a composite probe comprising a directing agent, a metal nanoparticle and an enzyme
US7888060B2 (en) * 2001-03-30 2011-02-15 Nanoprobes, Inc. Method for detecting a target using enzyme directed deposition of elemental metal
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
ATE433961T1 (de) 2002-02-08 2009-07-15 Conforma Therapeutics Corp Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften
AU2003264356A1 (en) * 2002-08-29 2004-04-30 Kyowa Hakko Kogyo Co., Ltd. Hsp90 FAMILY PROTEIN INHIBITORS
EP1583961B1 (en) * 2002-12-20 2007-03-21 The Registrar, Indian Institute of Science A novel assay to screen for anti-malarials
WO2004069999A2 (ja) * 2003-02-04 2004-08-19 Takeda Pharmaceutical Company Limited スクリーニング方法
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
EA010160B1 (ru) 2003-09-18 2008-06-30 Конформа Терапьютикс Корпорейшн Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
US7282493B2 (en) * 2003-12-23 2007-10-16 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
WO2005105077A1 (en) * 2004-04-28 2005-11-10 Massachusetts Eye & Ear Infirmary Inflammatory eye disease
US7259156B2 (en) * 2004-05-20 2007-08-21 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
MX2007004893A (es) * 2004-11-02 2007-06-14 Conforma Therapeutics Corp Metodos y composiciones para el tratamiento de leucemia linfocitica cronica.
WO2006052795A2 (en) * 2004-11-05 2006-05-18 University Of Rochester Methods of inhibiting the activity of hsp90 and/or aryl hydrocarbon receptor
EP1817295B1 (en) 2004-11-18 2012-11-07 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
KR20080004550A (ko) 2005-03-30 2008-01-09 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ９０-억제제로서 알키닐 피롤로피리미딘 및 관련유사체
CA2618628C (en) 2005-08-18 2014-11-18 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US8067412B2 (en) * 2006-08-11 2011-11-29 Universite De Strasbourg Macrocyclic compounds useful as inhibitors of kinases and HSP90
WO2008112873A2 (en) 2007-03-14 2008-09-18 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
EP3569251A1 (en) * 2007-06-25 2019-11-20 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US20110190237A1 (en) * 2008-01-15 2011-08-04 Nexgenix Pharmaceuticals Macrocyclic Prodrug Compounds Useful as Therapeutics
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
US20140294725A1 (en) 2011-07-08 2014-10-02 Sloan-Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
DE102011106984B3 (de) * 2011-07-08 2012-10-11 Sartorius Stedim Biotech Gmbh Microarray-Vorrichtung für das Screenen oder Auffinden von HSP90 Inhibitoren und von Inhibitoren weiterer krankheitsrelevanter Zielstrukturen
CN108107211B (zh) * 2011-07-22 2020-06-09 阿赛斯生物股份有限公司 用于改善的侧向流动测定法的单一垫条
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
HK1212618A1 (zh) 2012-10-16 2016-06-17 恩多塞特公司 含有非天然氨基酸的藥物遞送綴合物以及其使用方法
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
MX2015007446A (es) 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
WO2015038649A1 (en) 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
JP2017505777A (ja) 2014-01-29 2017-02-23 シンタ ファーマスーティカルズ コーポレーション 標的化治療薬
CA2941618A1 (en) 2014-03-03 2015-09-11 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2015143004A1 (en) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp. Targeted therapeutics
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
BR112018005322A2 (pt) 2015-09-18 2018-12-11 Arch Oncology, Inc. anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos
AU2017242893A1 (en) 2016-03-31 2018-08-09 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
CA3013407A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
KR102359766B1 (ko) 2016-04-01 2022-02-07 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서 치환된 인돌 화합물 유도체
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
DK3630724T3 (da) 2017-05-22 2021-07-26 Janssen Pharmaceuticals Inc Substituerede indolinderivater som inhibitorer af virusreplikation af denguevirus
JP7203764B2 (ja) 2017-05-22 2023-01-13 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての置換インドリン誘導体
IL299893A (en) 2017-06-20 2023-03-01 Madrigal Pharmaceuticals Inc prescribed medications
JP2020524156A (ja) 2017-06-20 2020-08-13 マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 標的治療薬を含む併用療法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL334257A1 (en) * 1999-07-06 2001-01-15 Cierpiak Andrzej Central heating water boiler
EP1265913A4 (en) * 2000-03-24 2004-07-14 Univ Duke CHARACTERIZATION OF THE INTERACTION BETWEEN GRP94 AND A LIGAND, AND CLEANING, SCREENING AND THERAPEUTIC PROCEDURES RELATING TO IT

Similar Documents

Publication Publication Date Title
JP2005520795A5 (enExample)
WO2007011907A3 (en) Alpha-synuclein antibodies and methods related thereto
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
EP1864998A3 (en) Binding molecules
WO2004078938A3 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2007002223A3 (en) Cd19 antibodies and their uses
WO2007000342A8 (en) Immunogenic composition
EP1581656A4 (en) MODULATION OF THE EXPRESSION OF HIF1a AND HIF2a
UA97473C2 (ru) Выделенное антитело, которое связывается с her-3, и его применение
WO2001092308A3 (en) Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
WO2006073941A3 (en) Polypeptides that bind br3 and uses thereof
WO2006076691A8 (en) Irta-2 antibodies and their uses
WO2005027733A3 (en) Biological markers for diagnosing multiple sclerosis
WO2005097185A3 (en) Irta-5 antibodies and their uses
WO2001064877A3 (en) Human schizophrenia gene
WO2007059064A3 (en) Fgf2-related methods for diagnosing and treating depression
WO2004024077A3 (en) Novel composition and methods for the treatment of psoriasis
EP2292666A3 (en) Neoplasm specific antibodies and uses thereof
WO2005124358A3 (en) Diagnosis and treatment of siglec-6 associated diseases
JP2004511237A5 (enExample)
WO2004069175A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON’S DISEASE AND OTHER α-SYNUCLEINOPATHIES
WO2023097219A3 (en) Anti-idiotype antibodies
WO2006108051A3 (en) Compositions and methods relating to alzheimer's disease
WO2004082568A3 (en) Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
WO2004104574A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)